References
- 1. Song L. Calcium and Bone Metabolism Indices. Adv Clin Chem. 2017;82:1-46. doi: 10.1016/bs.acc.2017.06.005. Epub 2017 Aug 7.10.1016/bs.acc.2017.06.005.Epub2017Aug7
- 2. Cunningham J, Locatelli F, Rodriguez M. Secondary Hyper-parathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Clin J Am Soc Nephrol, 2011;6(4): 913-921.
- 3. Krivoshiev S., A.-M. Borissova. From Renal Osteodys-trophy to Senile Osteoporosis. J Bulg Soc Endocrinol. 2003,8(2),68-75.
- 4. Edna D. Taniegra, M.D., Hyperparathyroidism. Am Fam Physician. 2004 Jan 15;69(2):333-339.
- 5. Nitta K, Yajima A, Tsuchiya K. Management of Osteoporosis in Chronic Kidney Disease. Intern Med. 2017 Dec 15; 56(24): 3271-3276.
- 6. Krivoshiev, St, E. Katerdzhieva, Ts. Baldev et al. Vascular calcifications in patients with terminal chronic renal failure treated with prolonged hemodialysis. Roentgenology and Radiology, 1994, Suppl., 39-42.
- 7. Martin, KJ, EA Gonzalez. Strategies to minimize bone disease in renal failure. Am J Kidney Dis, 38, 2001, 6, 1430-1436.
- 8. Llach F., F. V Forero. Secondary Hyperparathyreoidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney dis, 2001;38(5), Suppl 5, S20-S33.
- 9. Hsu, C.-Y., G. M. Ghertow. Elevations of serum phosphorus and potassium in mild to moderate chronic renal incufficiency. Nephrol Dial Transplant, 2002;17(6), 1419-1425.
- 10. Levey, A. S. Controlling the epidemic of cardiovascular disease in chronic renal disease:where do we start? Am. J. Kidney Dis., 1998;32(5), Suppl. 3, S5-S13.
- 11. Slatopolsky, E., A. Brown, A. Dusso. Phosphate control and osteodistrophy. Role of phosphorus in the pathogenesis of secondary hiperparathyreoidism. Am J Kidney Dis, 2001;37 (1), Suppl. 2, S54-S57.
- 12. Coen, G., P. Ballanti, E. Bonucci et al. Taggi, Renal osteodys-trophy in predialysis and haemodialysis patients: comparison of histologic patternsand diagnostic predictivity of intact PTH. Nephron, 2002;91(1), 103-111.
- 13. Hercz, G. Regulation of bone remodeling: impact of novel therapies. Semin Dial, 2001;14(1),55-60.
- 14. Hampson, G, Vaja S, Evans C et al. Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialsysis and continuous ambulatory peritoneal dialysis. Nephron, 2002;91(1), 94-102.
- 15. Yamamoto, T, Ozono K, Miyauchi A et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis, 2001;38(4), Suppl. 1 S161-S164.
- 16. London, G. Cardiovascular disease in end stage renal failure: role of calcium-phosphate disturbances and hyperparathyreoidism. J. Nephrol, 2002;15(2), 209-210.
- 17. Rao, D.S., M.S. Shih, R. Mohini. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N. Engl. J Med, 1993;328, 171-175.
- 18. Giannini, S, D’Angelo A, Carraro G et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol., 2001;56(5), 353-363.
- 19. Horwitz M. What medical options should be considered for the treatment of primary hyperparathyroidism? Clin Endocrinol. 2011;75(5):592-595.
- 20. Khan A., Bilezikian J., Kung A. et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89: 3319-25.
- 21. Moe S, Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-53.
- 22. [Guideline] National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42 (4 Suppl 3):S1-201.
- 23. [Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009,(113): S1-130.
- 24. Chronic Kidney Disease, Article in Madscape, Pradeep Arora, MD Assistant Professor of Medicine, University of Buffalo State University of New York School of Medicine, july 2018.
- 25. 25. Imaging in Secondary Hyperparathyroidism, Article in Madscape, Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR Consultant Radiologist and Honorary Professor, North Manchester General Hospital, nov. 2015.
- 26. Sharma AK, Masterson R, Holt SG, Toussaint ND. Emerging role of high-resolution imaging in the detection of renal osteo-dystrophy. Nephrology (Carlton). 2016;21(10):801-11.
- 27. Henriques JC, De Melo Castilho JC, Jacobs R et al. Severe secondary hyperparathyroidism and panoramic radiography parameters. Clin Oral Investig. 2013 Jul 12.
- 28. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017. 7:1-59.
- 29. Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital, 2017.
- 30. Andrew L. Lundquist; Sagar U. Nigwekar, Curr Opin Nephrol Hypertens. 2016;25(2):120-126.